FORGE/FORWARD
Command CenterExploreCompetitive LandscapeContentionChangesData & methodology

Organization profile

Taisho Pharmaceutical

Confirmed Organization

RIH-confirmed Organization based on evidence-backed relationships between published Applicant legal entities. This is not an ICANN designation.

Represented Applicant legal entities: 12026 Applications: 3Contention memberships: 0Unique contention sets: 0Brand Applications: 3

At a glance

Applicant entities

1

2026 Applications

3

Brand Applications

3 of 3

In initial contention

0

Unique contention sets

0

Contention memberships

0

RIH maps 3 represented Applications across 1 Applicant legal entity to Taisho Pharmaceutical.

Confirmed-subset concentration context

Application portfolio rank #28 · 3 Applications · 0.3% of confirmed-subset Applications

Contention membership rank #96 · 0 memberships · 0.0% of confirmed-subset memberships · 0 official sets touched

Confirmed subset ≠ complete round. Unresolved Applicants remain source Applicants and are not grouped into Organizations.

Frequent contention counterparts

No Confirmed Organization counterpart is present in the current official contention data. Unresolved or non-Confirmed memberships may still exist in official sets.

Co-membership in official contention sets only — not a commercial-outcome claim.

Explore applicationsCompetitive LandscapeContentionView Applicant Profile

Represented Applicant entities mapped to this Organization

These are ICANN Applicant legal entities — not subsidiaries or brands unless evidence establishes that relationship.

  • Taisho Pharmaceutical Co., Ltd.3 apps · 3 Brand · 0 contention memberships

    JP · AP · taisho.co.jp

Application portfolio

Brand Applications: 3 of 3. Each row keeps its legal Applicant attribution — Taisho Pharmaceutical is not the ICANN Applicant.

  • .lipovitanBrand

    TPCL2648T-T11392

    Taisho Pharmaceutical Co., Ltd.

    Open in Explore
  • .taishoBrand

    TPCL2648T-T85554

    Taisho Pharmaceutical Co., Ltd.

    Open in Explore
  • .upsaBrand

    TPCL2648T-T93473

    Taisho Pharmaceutical Co., Ltd.

    Open in Explore
StringApplication IDApplicantBrandStatusContention
.lipovitanTPCL2648T-T11392Taisho Pharmaceutical Co., Ltd.BrandActive—
.taishoTPCL2648T-T85554Taisho Pharmaceutical Co., Ltd.BrandActive—
.upsaTPCL2648T-T93473Taisho Pharmaceutical Co., Ltd.BrandActive—

Contention

Taisho Pharmaceutical has 0 Application contention memberships in 0 unique contention sets, from 0 Applicant legal entities represented in those sets. Application memberships and unique sets are not interchangeable.

Applications in contention
0
Unique sets
0
External counterpart Applicants
0

No official initial contention memberships for this Organization.

Identity / relationship evidence

Taisho Pharmaceutical: 1 Confirmed Applicant mappings. Evidence types observed: self-identity / Brand evidence.

Inspect by Applicant
  • Taisho Pharmaceutical Co., Ltd.

    Website: taisho.co.jp

    Direct parent: Taisho Pharmaceutical Holdings Co., Ltd.

    Ultimate parent: Taisho Pharmaceutical Holdings Co., Ltd.

    • Self-Organization: Taisho Pharmaceutical (operating company)
    • B APS first-party: wholly owned operating company within Holdings group
    • Holdings named as material shareholder / parent — separate from Organization
    • Existing key match: no · new key taisho-pharmaceutical

Public RSP posture

Public Main-RSP capability among mapped Applicants: 0 · No public Main-RSP: 1 · Via confirmed Organization: 0

Selected RSP is not established by the public Applicant data. No Organization-level RSP inference beyond accepted Applicant matching rules.

Recent changes

No material public Application or contention changes recorded for this Organization since monitoring began.

Open Change Intelligence

Sources

  • Organization resolution: RIH evidence-backed mapping (steward Confirmed)
  • Applications: ICANN APS / represented Application publication
  • Contention: official initial contention memberships
  • RSP: official evaluated-RSP source where applicable
  • Cross-round: accepted historical identity evidence where confirmed
Data & methodology